Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496820 | 0.81 | DGAT1 (0.35) | NPC1DGAT1 | |
| SCHEMBL29953218 | 0.77 | — | — | |
| SCHEMBL19992397 | 0.77 | NPC1 (0.32) | NPC1DGAT1 | |
| SCHEMBL31308722 | 0.76 | DGAT1 (0.35) | NPC1DGAT1 | |
| SCHEMBL20744490 | 0.76 | DGAT1 (0.40) | NPC1DGAT1 | |
| SCHEMBL30789772 | 0.76 | DGAT1 (0.33) | NPC1DGAT1 | |
| SCHEMBL401354 | 0.76 | ALDH1A1 (0.39) | NPC1DGAT1 | |
| SCHEMBL3389626 | 0.76 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL8257898 | 0.76 | P2RX7 (0.35) | DGAT1 | |
| SCHEMBL31741697 | 0.75 | DGAT1 (0.32) | NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117186119-A | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7635703-B2 | Imidazole substituted pyrazole kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-22 | — | — | US | disclosed |
| US-20080103172-A1 | IMIDAZOLE SUBSTITUTED PYRAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008048503-A2 | IMIDAZOLE SUBSTITURED PYRAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | WO | disclosed |
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| EP-1751119-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | NPC1 107/4885DGAT1 3064/4885 |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | NPC1 3125/4885DGAT1 2745/4885 |
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | VIP, CCKBR, HRH2 | NPC1 679/4885DGAT1 3316/4885 |
| US-20080103172-A1 | IMIDAZOLE SUBSTITUTED PYRAZOLE KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | NPC1 2462/4885DGAT1 3840/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | NPC1 1348/4885DGAT1 2658/4885 |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | HCAR1, HDAC1, H1-0 | NPC1 2166/4885DGAT1 3136/4885 |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | NPC1 2102/4885DGAT1 3106/4885 |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | NPC1 2102/4885DGAT1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.